How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

760 results for

Ergotamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. (Abstract)

The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Dihydroergotamine or ergotamine are the most effective preparations for aborting acute attacks of migraine without aura.The aim of our study was to compare the efficacy and safety of ergotamine based five-component drug combination and sumatriptan in the treatment of moderate to severe acute attacks of migraine without aura.The study (...) was designed as a randomized, double-blind, double-dummy, placebo-controlled, parallel arm, multi-center clinical trial. The enrolled patients having migraine without aura were randomized to one of the study arms, ergotamine based five-component drug combination or sumatriptan.In total, 201 patients were randomized to one of the treatment arms. Higher percentage of patients was completely free of the headache two hours after dose administration in the ergotamine-based medication group compared

2019 Hippokratia Controlled trial quality: uncertain

2. Contractile Response of Bovine Lateral Saphenous Vein to Ergotamine Tartrate Exposed to Different Concentrations of Molecularly Imprinted Polymer Full Text available with Trip Pro

Contractile Response of Bovine Lateral Saphenous Vein to Ergotamine Tartrate Exposed to Different Concentrations of Molecularly Imprinted Polymer Ergot alkaloids, in their active isomeric form, affect animal health and performance, and adsorbents are used to mitigate toxicities by reducing bioavailability. Adsorbents with high specificity (molecularly imprinted polymers: MIP) adsorb ergot alkaloids in vitro, but require evaluation for biological implications. Using ex vivo myography, synthetic (...) polymers were evaluated for effects on the bioactivity of ergotamine tartrate (ETA). Polymers were first evaluated using isotherms. Lateral saphenous veins were collected from 17 steers for four independent studies: dose response of ETA, adsorbent dose response, validation of pre-myograph incubation conditions and MIP/ non-molecularly imprinted polymer (NIP) comparison. Norepinephrine normalized percent contractile response to increasing ETA exhibited a sigmoidal dose response (max: 88.47 and log

2018 Toxins

3. Ergotamine Use and Overuse in Taiwan: A Retrospective Cohort Study. (Abstract)

Ergotamine Use and Overuse in Taiwan: A Retrospective Cohort Study. The aim of this study was to investigate the pattern of ergotamine prescription and overuse in Taiwan.Ergotamine is a frequently prescribed medication for the treatment of migraine, although excessive use may lead to medication-overuse headache.We conducted a retrospective cohort study by using the Longitudinal Health Insurance Database 2005 in Taiwan. Patients enrolled in the study were between the ages of 18 and 80 years (...) , received at least two prescriptions of ergotamine, and follow-up for more than 1 year at outpatient clinics during 1999 to 2013. Each ergotamine prescription was converted into a defined daily dose (DDD) and patients were sorted into two groups: occasional users, having fewer than 3 consecutive months of use, and regular users, with 3 consecutive months of use or more. Regular users were further divided into overusers (DDDs ≥ 10 per month) and non-overusers.A total of 41,023 migraine patients were

2017 Headache

4. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. (Abstract)

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. The mixed serotonin (5-HT) 1A/2A/2B/2C/6/7 receptor agonist psilocybin dose-dependently induces an altered state of consciousness (ASC) that is characterized by changes in sensory perception, mood, thought, and the sense of self. The psychological effects of psilocybin are primarily mediated by 5-HT2A receptor activation. However (...) , accumulating evidence suggests that 5-HT1A or an interaction between 5-HT1A and 5-HT2A receptors may contribute to the overall effects of psilocybin. Therefore, we used a double-blind, counterbalanced, within-subject design to investigate the modulatory effects of the partial 5-HT1A agonist buspirone (20mg p.o.) and the non-hallucinogenic 5-HT2A/1A agonist ergotamine (3mg p.o.) on psilocybin-induced (170 µg/kg p.o.) psychological effects in two groups (n=19, n=17) of healthy human subjects. Psychological

2017 European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology Controlled trial quality: uncertain

5. Ergotamine

Ergotamine Ergotamine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Ergotamine Ergotamine Aka: Ergotamine , Wigraine II. Indications (...) on the term "Ergotamine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Ergotamine (C0014710) Definition (MSH) A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS. Definition (NCI) A naturally occurring ergot alkaloid with vasoconstrictor and analgesic property. Ergotamine selectively binds and activates

2018 FP Notebook

6. Tolfenamic acid is as effective as ergotamine during migraine attacks. (Abstract)

Tolfenamic acid is as effective as ergotamine during migraine attacks. Tolfenamic acid (a potent inhibitor of prostaglandin biosynthesis), ergotamine tartrate, acetylsalicylic acid, or placebo was administered during 160 migraine attacks in twenty women in a double-blind, cross-over study. Tolfenamic acid and ergotamine were equally effective in reducing the duration and intensity of attacks, but side-effects, especially nausea, were less common with tolfenamic acid. This probably accounted

1979 Lancet Controlled trial quality: uncertain

7. THE EFFECT OF DEMEROL, ERGOTAMINE, AND DIHYDRO-ERGOTAMINE ON MORTALITY AFTER CORONARY OCCLUSION IN DOGS Full Text available with Trip Pro

THE EFFECT OF DEMEROL, ERGOTAMINE, AND DIHYDRO-ERGOTAMINE ON MORTALITY AFTER CORONARY OCCLUSION IN DOGS 18610063 2008 08 22 2018 12 01 0007-0769 9 2 1947 Apr British heart journal Br Heart J THE EFFECT OF DEMEROL, ERGOTAMINE, AND DIHYDRO-ERGOTAMINE ON MORTALITY AFTER CORONARY OCCLUSION IN DOGS. 85-95 Manning G W GW Banting and Best Department of Medical Research, Banting Institute, Toronto, Canada. Caudwell G C GC eng Journal Article England Br Heart J 0370634 0007-0769 9E338QE28F Meperidine (...) PR834Q503T Ergotamine OM Animals Coronary Occlusion Coronary Vessels Dogs Ergotamine Heart Humans Meperidine Vascular Diseases 4713:976m CORONARY VESSELS/occlusion 1947 4 1 0 0 1947 4 1 0 1 1947 4 1 0 0 ppublish 18610063 PMC481012 Can Med Assoc J. 1944 Dec;51(6):509-17 20323279 Can Med Assoc J. 1946 Jul;55(1):43-6 20323839 Can Med Assoc J. 1933 Aug;29(2):122-4 20319191

1947 British Heart Journal

8. Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure. Full Text available with Trip Pro

Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure. Severely affected patients with autonomic failure require pressor agents to counteract the blood pressure fall and improve presyncopal symptoms upon standing. Previous studies suggest that combination ergotamine and caffeine may be effective in the treatment of autonomic failure, but the efficacy of this drug has not been evaluated in controlled trials. Therefore, we compared (...) the effects of ergotamine/caffeine on seated blood pressure and orthostatic tolerance and symptoms in 12 primary autonomic failure patients without history of coronary artery disease. Patients were randomized to receive a single oral dose of placebo, midodrine (5-10 mg), or ergotamine and caffeine (1 and 100 mg, respectively) in a single-blind, crossover study. Blood pressure was measured while patients were seated and after standing for up to 10 min, at baseline and at 1 h post-drug. Ergotamine/caffeine

2014 Frontiers in physiology Controlled trial quality: uncertain

9. Ergotamine-induced tricuspid valvulopathy presenting as recurrent pleural effusions. (Abstract)

Ergotamine-induced tricuspid valvulopathy presenting as recurrent pleural effusions.

2014 Chest

10. Ergotamine

Ergotamine Ergotamine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Ergotamine Ergotamine Aka: Ergotamine , Wigraine II. Indications (...) on the term "Ergotamine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Ergotamine (C0014710) Definition (MSH) A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS. Definition (NCI) A naturally occurring ergot alkaloid with vasoconstrictor and analgesic property. Ergotamine selectively binds and activates

2015 FP Notebook

11. Ergotamine-Associated Valvulopathy with Recurrent Chylous Pleural Effusion Full Text available with Trip Pro

Ergotamine-Associated Valvulopathy with Recurrent Chylous Pleural Effusion We report a rare case of ergotamine-associated mitral stenosis in a 55-year-old woman who presented with recurrent chylous pleural effusion. Echocardiographic, gross, and microscopic features of the mitral valve were consistent with chronic ergotamine-induced valvulopathy. We conclude that medication-induced valvulopathy should be included in the differential diagnosis of valvular heart disease. In addition, cardiac (...) function should be monitored before and during long-term therapy with ergotamine or ergotamine-derived dopamine agonists.

2012 Texas Heart Institute Journal

12. An unusual cause of chest pain: Acute coronary syndrome following administration of ergotamine tartrate Full Text available with Trip Pro

An unusual cause of chest pain: Acute coronary syndrome following administration of ergotamine tartrate For many years, ergotamine has been used for the acute treatment of migraine. Ergotamine may produce coronary vasospasm, which is often associated with ischemic electrocardiography changes and angina pectoris. A 62-year-old woman who was admitted to the emergency department because of chest pain is described. She had a history of severe migraine attacks and started to use ergotamine tartrate (...) 0.75 mg daily the day before. Electrocardiography revealed sinus tachycardia with left anterior hemiblock and T wave inversion in the precordial leads. Cardiac biomarker levels were elevated. After discontinuation of the drug and initiation of vasodilator treatment, her chest pain resolved. Patients with migraine may have an underlying vasospastic disorder predisposing them to coronary artery spasm. Physicians should be alerted to potential cardiac vasospastic effects of low-dose ergotamine

2012 Experimental & Clinical Cardiology

13. Bilateral Thrombophlebitis After a Single Dose of Ergotamine Tartrate for Migraine Full Text available with Trip Pro

Bilateral Thrombophlebitis After a Single Dose of Ergotamine Tartrate for Migraine 13596640 2000 07 01 2018 12 01 0007-1447 2 5110 1958 Dec 13 British medical journal Br Med J Bilateral thrombophlebitis after a single dose of ergotamine tartrate for migraine. 1452-3 CARTER E R ER eng Journal Article England Br Med J 0372673 0007-1447 0 Amides PR834Q503T Ergotamine OM Amides adverse effects Ergotamine Humans Migraine Disorders therapy Thrombophlebitis etiology 5935:26148:203:373:581 DIETHYLAMIDE

1958 British medical journal

14. The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog Full Text available with Trip Pro

The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog The effect of ergotamine and dihydroergotamine on the cerebral circulation was studied in the dog, anaesthetized with chloralose, by recording the intracranial venous pressure and the venous outflow from the superior cerebral vein. Under optimal experimental conditions, ergotamine (5 to 10 mug./kg.) and dihydroergotamine (100 mug./kg.) gave a marked and long-lasting cerebral (...) vasoconstriction accompanied by a slight hypertension. The cerebral vasoconstriction provoked by ergotamine may be very small and was sometimes absent when the cerebral blood-flow was low. This vasoconstrictor effect is more pronounced the higher the initial intracranial venous pressure and hence the cerebral blood-flow. After the induction of a cerebral vasodilatation by 48/80 or strychnine, the vasoconstrictor action of ergotamine was more pronounced. The effect was not observed when CO(2) was employed

1957 British journal of pharmacology and chemotherapy

15. ERGOTAMINE TREATMENT OF MIGRAINE Full Text available with Trip Pro

ERGOTAMINE TREATMENT OF MIGRAINE 13662660 2000 07 01 2018 12 01 0007-1447 2 5141 1959 Jul 18 British medical journal Br Med J ERGOTAMINE treatment of migraine. 69-70 eng Journal Article England Br Med J 0372673 0007-1447 0 Cardiovascular Agents 0 Ergot Alkaloids 0 Oxytocics PR834Q503T Ergotamine OM Cardiovascular Agents Ergot Alkaloids therapeutic use Ergotamine Migraine Disorders therapy Oxytocics 5936:36701:189:346 ERGOT ALKALOIDS/therapeutic use MIGRAINE/therapy 1959 7 18 1959 7 18 0 1 1959

1959 British medical journal

16. A randomized controlled trial of ergotamine tartrate. (Abstract)

A randomized controlled trial of ergotamine tartrate. 4908199 1970 05 13 2015 11 19 0007-1242 24 1 1970 Feb British journal of preventive & social medicine Br J Prev Soc Med A randomized controlled trial of ergotamine tartrate. 65 Waters W E WE eng Clinical Trial Journal Article Randomized Controlled Trial England Br J Prev Soc Med 0372672 0007-1242 0 Placebos PR834Q503T Ergotamine IM Clinical Trials as Topic Ergotamine adverse effects therapeutic use Female Headache diagnosis Humans Migraine

1970 British journal of preventive & social medicine Controlled trial quality: predicted high

17. A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine. (Abstract)

A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine. 4552744 1972 06 15 2013 11 21 0007-0947 26 2 1972 Feb The British journal of clinical practice Br J Clin Pract A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine. 76-9 Yuill G M GM Swinburn W R WR Liversedge L A LA eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial England Br J Clin Pract 0372546 0007-0947 0 Amines 0 Methylamines 0 (...) Sympathomimetics PR834Q503T Ergotamine Y7L24THH6T isometheptene IM Amines adverse effects therapeutic use Diarrhea chemically induced Ergotamine adverse effects therapeutic use Female Humans Male Methylamines adverse effects therapeutic use Migraine Disorders drug therapy Sympathomimetics adverse effects therapeutic use Wakefulness drug effects 1972 2 1 1972 2 1 0 1 1972 2 1 0 0 ppublish 4552744

1972 The British journal of clinical practice Controlled trial quality: uncertain

18. The Use of Ergotamine Tartrate in Migraine Full Text available with Trip Pro

The Use of Ergotamine Tartrate in Migraine 20320103 2010 06 24 2010 06 24 0008-4409 33 6 1935 Dec Canadian Medical Association journal Can Med Assoc J The Use of Ergotamine Tartrate in Migraine. 664-5 McNaughton F L FL eng Journal Article Canada Can Med Assoc J 0414110 0008-4409 2010 3 24 6 0 1935 12 1 0 0 1935 12 1 0 1 ppublish 20320103 PMC1561491

1935 Canadian Medical Association Journal

19. CLINICAL COMPARISON OF ERGOTOXINE AND ERGOTAMINE: A REPORT TO THE THERAPEUTIC TRIALS COMMITTEE OF THE MEDICAL RESEARCH COUNCIL Full Text available with Trip Pro

CLINICAL COMPARISON OF ERGOTOXINE AND ERGOTAMINE: A REPORT TO THE THERAPEUTIC TRIALS COMMITTEE OF THE MEDICAL RESEARCH COUNCIL 20776878 2011 03 31 2011 03 31 0007-1447 1 3726 1932 Jun 04 British medical journal Br Med J CLINICAL COMPARISON OF ERGOTOXINE AND ERGOTAMINE: A REPORT TO THE THERAPEUTIC TRIALS COMMITTEE OF THE MEDICAL RESEARCH COUNCIL. 1022-4 Moir C C eng Journal Article England Br Med J 0372673 0007-1447 2010 8 27 6 0 1932 6 4 0 0 1932 6 4 0 1 ppublish 20776878 PMC2521092

1932 British medical journal

20. The behaviour of the liver glycogen during decerebration hyperglycæmia and the influence of atropine and of ergotamine on this condition Full Text available with Trip Pro

The behaviour of the liver glycogen during decerebration hyperglycæmia and the influence of atropine and of ergotamine on this condition 16994502 2007 02 05 2008 11 20 0022-3751 80 3 1933 Dec 30 The Journal of physiology J. Physiol. (Lond.) The behaviour of the liver glycogen during decerebration hyperglycaemia and the influence of atropine and of ergotamine on this condition. 296-304 Long M L ML eng Journal Article England J Physiol 0266262 0022-3751 1933 12 30 0 0 1933 12 30 0 1 1933 12 30 0

1933 The Journal of physiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>